title: Left ventricular mass regression after aortic valve replacement with CryoLife-O'Brien stentless aortic bioprosthesis.
abstract: OBJECTIVE
  Left ventricular (LV) hypertrophy has been shown adversely to affect LV function and late outcome after aortic valve replacement (AVR). The study aim was to assess the time course of LV mass regression (LVMR) after AVR with a CryoLife-O'Brien stentless bioprosthesis, and to identify factors affecting late reduction of myocardial hypertrophy.
  
  
  METHODS
  In total, 113 patients (60 males, 73 females; mean age 70.9+/-6.5 years) were studied by echocardiography preoperatively, at discharge, at six and 12 months postoperatively, and yearly thereafter. LV diameter and thickness were measured using M-mode echocardiography; LV mass was calculated using the Devereux formula and indexed by body surface area (BSA).
  
  
  RESULTS
  LV end-systolic diameter, end-diastolic diameter, septal thickness and wall thickness decreased significantly after surgery (p <0.001). LV mass index (LVMI) was reduced by 16.6, 13.6, 10.1, 3.1, 3.3, 1.7, 2.6, and 1.8% at discharge and at 6 months and 1, 2, 3, 4, 5, and 6 years, respectively. Most LVMR occurred within the first year, with further (not significant) reductions at later examinations. Male sex (p = 0.002), arterial blood pressure > or =150 mmHg (p <0.001), LV ejection fraction (LVEF) < or =35% (p = 0.01), NYHA functional class > or = III (p = 0.01), atrial fibrillation (p <0.001), mean transvalvular gradient > or =40 mmHg (p = 0.001), and prevalent aortic incompetence (p <0.001) were factors influencing LVMR, independently of baseline effective orifice area and prosthesis size.
  
  
  CONCLUSIONS
  AVR with the CryoLife-O'Brien stentless prosthesis resulted in significant LVMR. These findings encourage the use of this bioprosthesis in appropriate patients.
authors.affiliation: Department of Cardiovascular Sciences, General Hospital S. Maria della Misericordia, Udine, Italy. sandrogelsomino@virgilio.it
authors.forename: S
authors.initials: S
authors.lastname: Gelsomino
authors.forename: R
authors.initials: R
authors.lastname: Frassani
authors.forename: G
authors.initials: G
authors.lastname: Morocutti
authors.forename: L
authors.initials: L
authors.lastname: Porreca
authors.forename: V
authors.initials: V
authors.lastname: Tursi
authors.forename: G
authors.initials: G
authors.lastname: Masullo
authors.forename: R
authors.initials: R
authors.lastname: Lumini
authors.forename: U
authors.initials: U
authors.lastname: Livi
mesh_terms: D000368:Aged; D001022:Aortic Valve Insufficiency / Q000150:complications* / Q000601:surgery*; D001024:Aortic Valve Stenosis / Q000150:complications* / Q000601:surgery*; D001705:Bioprosthesis; D005260:Female; D019918:Heart Valve Prosthesis Implantation; D006439:Hemodynamics / Q000502:physiology; D006801:Humans; D017379:Hypertrophy, Left Ventricular / Q000150:complications* / Q000601:surgery*; D007558:Italy / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D015995:Prevalence; D012044:Regression Analysis; D012307:Risk Factors; D012737:Sex Factors; D012969:Sodium Fluoride / Q000627:therapeutic use*; D015607:Stents; D013997:Time Factors; D016896:Treatment Outcome; D020257:Ventricular Remodeling / Q000502:physiology
chemical_list: C007157:cryolite; D012969:Sodium Fluoride